MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06361108 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

DRUG: YJ001 for Spray Use
DRUG: Placebo of YJ001 for Spray Use

Sponsor

Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.